White Paper

Secure The Cell Therapy Supply Chain From Bench To Bedside

Source: Cytiva

Cell therapy development is changing healthcare. Due to the increasing availability of cell therapy treatments, thousands of patients worldwide have new hope for a positive disease outcome. As we scale up to treat more patients, there will be an increase in the challenges related to the vein-to-vein workflow.

While current approaches can manage the existing volume of cell therapy shipments, scaling these treatments up and out will increase pressure on existing cryogenic logistics networks. Considering and addressing these challenges early in a therapy’s development could help reduce the risk of future supply chain disruptions.

Here, we consider the challenges and risks associated with the cryogenic supply chain for cell therapies and provide considerations for mitigation strategies.


Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Outsourced Pharma? Subscribe today.

Subscribe to Outsourced Pharma X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Outsourced Pharma